{"protocolSection": {"identificationModule": {"nctId": "NCT00386607", "orgStudyIdInfo": {"id": "CSPV100A2301"}, "secondaryIdInfos": [{"id": "CSPV100A2301E1"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.", "officialTitle": "A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Safety and Tolerability of the Triple Combination of Aliskiren/Valsartan/Hydrochlorothiazide(HCTZ)"}, "statusModule": {"statusVerifiedDate": "2014-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-10"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-10", "studyFirstSubmitQcDate": "2006-10-10", "studyFirstPostDateStruct": {"date": "2006-10-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-20", "resultsFirstSubmitQcDate": "2011-04-07", "resultsFirstPostDateStruct": {"date": "2011-05-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-01-14", "lastUpdatePostDateStruct": {"date": "2014-02-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the combination of aliskiren/valsartan/Hydrochlorothiazide(HCTZ)."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, aliskiren, valsartan, HCTZ, blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 601, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Core Treatment", "type": "EXPERIMENTAL", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure \u2265 140 and/or mean sitting Diastolic Blood Pressure \u2265 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.", "interventionNames": ["Drug: Aliskiren", "Drug: Valsartan"]}, {"label": "Extension Treatment", "type": "EXPERIMENTAL", "description": "For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.\n\nThe HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was \u2265140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was \u226590 mmHg for 2 consecutive visits.", "interventionNames": ["Drug: Aliskiren", "Drug: Valsartan", "Drug: Hydrochlorothiazide (HCTZ)"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 300 mg", "armGroupLabels": ["Core Treatment", "Extension Treatment"]}, {"type": "DRUG", "name": "Valsartan", "description": "Valsartan 320 mg", "armGroupLabels": ["Core Treatment", "Extension Treatment"]}, {"type": "DRUG", "name": "Hydrochlorothiazide (HCTZ)", "description": "Hydrochlorothiazide (HCTZ) 12.5-25 mg", "armGroupLabels": ["Extension Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Overall Percentage of Patients With Adverse Events", "timeFrame": "Month 12"}, {"measure": "Overall Percentage of Patients With Adverse Events", "description": "adverse event data obtained from both the core study and the 6 month extension study.", "timeFrame": "Month 18"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure.", "timeFrame": "Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54"}, {"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure.", "timeFrame": "Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg", "timeFrame": ".Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure", "timeFrame": "Baseline and Month 18"}, {"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure", "timeFrame": "Baseline and Month 18"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment", "timeFrame": "Month 18"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria: -\n\n* Male and female outpatients 18 years of age and older.\n* For newly diagnosed/untreated patients with essential hypertension defined as msDBP \u2265 90 and \\< 110 mmHg at Visit 1 and Visit 4\n* For previously treated patients with essential hypertension defined as msDBP \u2265 90 and \\< 110 mmHg after 2 to 4 weeks of washout (Visit 4)\n* Patients who were eligible and able to participate in the study and who consented to do so after the purpose and nature of the investigation had been clearly explained to them (written informed consent).\n\nExclusion Criteria:\n\n* Severe hypertension (msDBP \u2265 110 mmHg and/or msSBP \u2265 180 mmHg)\n* Women of child-bearing potential, unless they met definition of post-menopausal or were using acceptable methods of contraception.\n* History or evidence of a secondary form of hypertension.\n* History of hypertensive encephalopathy or cerebrovascular accident.\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative Centers", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Investigative Centers", "city": "Canada", "country": "Canada"}, {"facility": "Investigative Centers", "city": "Germany", "country": "Germany"}, {"facility": "Investigative Centers", "city": "Netherlands", "country": "Netherlands"}]}, "referencesModule": {"references": [{"pmid": "21062137", "type": "DERIVED", "citation": "Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Ritter S, Zhang J. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr Med Res Opin. 2010 Dec;26(12):2841-9. doi: 10.1185/03007995.2010.528282. Epub 2010 Nov 9."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Core Treatment", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}, {"id": "FG001", "title": "Extension Treatment", "description": "For patients entering into extension, those previously treated with HCTZ (12.5 or 25 mg) in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension.\n\nThose patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.\n\nThe HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the msSBP was \u2265140 mmHg and/or the msDBP was \u226590 mmHg for 2 consecutive visits."}], "periods": [{"title": "Core", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "601"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "486"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Condition no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Extension", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "162"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "145"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Core Treatment", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "601"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.0", "spread": "11.20"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "271"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "330"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Overall Percentage of Patients With Adverse Events", "populationDescription": "Treated population: All patients who received at least one dose of Aliskiren/Valsartan", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "Month 12", "groups": [{"id": "OG000", "title": "Core Treatment- Aliskiren/Valsartan & Aliskiren/Valsartan/HCTZ", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "601"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "76.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure.", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54", "groups": [{"id": "OG000", "title": "Core Treatment", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "601"}]}], "classes": [{"title": "Week 2 (Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.9", "spread": "7.14"}]}]}, {"title": "Week 4 (Visit 6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.8", "spread": "7.83"}]}]}, {"title": "Week 6 (Visit 7)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.8", "spread": "8.09"}]}]}, {"title": "Week 10 (Visit 8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.5", "spread": "8.26"}]}]}, {"title": "Week 14 (Visit 9)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.7", "spread": "7.87"}]}]}, {"title": "Week 18 (Visit 10)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.0", "spread": "8.00"}]}]}, {"title": "Week 28 (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.2", "spread": "7.24"}]}]}, {"title": "Week 41 (Visit 12)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.2", "spread": "7.60"}]}]}, {"title": "Week 54 (Visit 13)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.2", "spread": "7.96"}]}]}, {"title": "Endpoint (value at week 54 or LOCF)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.4", "spread": "8.75"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure.", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54", "groups": [{"id": "OG000", "title": "Core Treatment", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "601"}]}], "classes": [{"title": "Week 2 (Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.0", "spread": "12.42"}]}]}, {"title": "Week 4 (Visit 6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.0", "spread": "14.03"}]}]}, {"title": "Week 6 (Visit 7)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.6", "spread": "14.10"}]}]}, {"title": "Week 10 (Visit 8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.4", "spread": "14.37"}]}]}, {"title": "Week 14 (Visit 9)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.7", "spread": "13.42"}]}]}, {"title": "Week 18 (Visit 10)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.6", "spread": "14.01"}]}]}, {"title": "Week 28 (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.3", "spread": "13.70"}]}]}, {"title": "Week 41 (Visit 12)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.3", "spread": "13.27"}]}]}, {"title": "Week 54 (Visit 13)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.3", "spread": "14.51"}]}]}, {"title": "Endpoint (value at week 54 or LOCF)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.5", "spread": "16.40"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": ".Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54", "groups": [{"id": "OG000", "title": "Core Treatment", "description": "Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP \u2265 140 and/or msDBP \u2265 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "601"}]}], "classes": [{"title": "Week 2 (Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.8"}]}]}, {"title": "Week 4 (Visit 6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.9"}]}]}, {"title": "Week 6 (Visit 7)", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}]}]}, {"title": "Week 10 (Visit 8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.8"}]}]}, {"title": "Week 14 (Visit 9)", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.7"}]}]}, {"title": "Week 18 (Visit 10)", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.4"}]}]}, {"title": "Week 28 (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.9"}]}]}, {"title": "Week 41 (Visit 12)", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.2"}]}]}, {"title": "Week 54 (Visit 13)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.7"}]}]}, {"title": "Endpoint (value at week 54 or LOCF)", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Month 18", "groups": [{"id": "OG000", "title": "Extension Treatment", "description": "All patients receiving aliskiren / valsartan / HCTZ in extension study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.3", "spread": "8.52"}]}]}]}, {"type": "PRIMARY", "title": "Overall Percentage of Patients With Adverse Events", "description": "adverse event data obtained from both the core study and the 6 month extension study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "Month 18", "groups": [{"id": "OG000", "title": "Core and Extension Treatment - Aliskiren/Valsartan/HCTZ", "description": "All patients receiving aliskiren / valsartan / HCTZ during either core or extension study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Month 18", "groups": [{"id": "OG000", "title": "Extension Treatment", "description": "All patients receiving aliskiren / valsartan / HCTZ in extension study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-28.8", "spread": "14.80"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment", "populationDescription": "Treated population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Month 18", "groups": [{"id": "OG000", "title": "Extension Treatment", "description": "All patients receiving aliskiren / valsartan / HCTZ in extension study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "18 months", "description": "All patients who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "Core Period: Aliskiren 150 mg / Valsartan 160 mg Alone", "description": "Core Period: Aliskiren 150 mg /Valsartan 160 mg alone", "seriousNumAffected": 3, "seriousNumAtRisk": 601, "otherNumAffected": 49, "otherNumAtRisk": 601}, {"id": "EG001", "title": "Core Period: Aliskiren 300 mg / Valsartan 320 mg Alone", "description": "Core Period: Aliskiren 300 mg /Valsartan 320 mg alone", "seriousNumAffected": 14, "seriousNumAtRisk": 585, "otherNumAffected": 185, "otherNumAtRisk": 585}, {"id": "EG002", "title": "Core Period: Aliskiren / Valsartan", "description": "Core Period: Aliskiren/Valsartan", "seriousNumAffected": 17, "seriousNumAtRisk": 601, "otherNumAffected": 215, "otherNumAtRisk": 601}, {"id": "EG003", "title": "Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg", "description": "Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg", "seriousNumAffected": 3, "seriousNumAtRisk": 306, "otherNumAffected": 47, "otherNumAtRisk": 306}, {"id": "EG004", "title": "Core and Extension: Aliskiren / Valsartan / HCTZ 25 mg", "description": "Core and Extension: Aliskiren/Valsartan/HCTZ 25 mg", "seriousNumAffected": 6, "seriousNumAtRisk": 137, "otherNumAffected": 26, "otherNumAtRisk": 137}, {"id": "EG005", "title": "Core and Extension: Total", "description": "Core and Extension: Total includes all study patients, treated with Aliskiren/Valsartan or Aliskiren//valsartan/HCTZ during core or extension.", "seriousNumAffected": 26, "seriousNumAtRisk": 601, "otherNumAffected": 251, "otherNumAtRisk": 601}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 601}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Ventricular hypokinesia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Retinal vascular thrombosis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Gallbladder disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Clostridium difficile colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Hepatitis B", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Peritoneal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Post-traumatic pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Therapeutic agent toxicity", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 601}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 601}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Substance abuse", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 601}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 34, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 42, "numAtRisk": 601}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 34, "numAtRisk": 601}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 39, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 43, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 54, "numAtRisk": 601}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 28, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 38, "numAtRisk": 601}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 32, "numAtRisk": 601}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 39, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 49, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 61, "numAtRisk": 601}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 45, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 50, "numAtRisk": 601}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 601}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 585}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 601}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 306}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG005", "numAffected": 31, "numAtRisk": 601}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Open label study with no comparator treatment/arm."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}